1613144-80-1
Chemical Structure
Cabiralizumab
Synonym(s): FPA 008; Anti-Human CSF1R Recombinant Antibody
- CAS No.: 1613144-80-1
- Formula:N/A
- Molecular Weight:(146.02 kDa)
IUPAC Name: tert-butyl (3-(3-formylbenzyl)phenyl)carbamate
SMILES: [Cabiralizumab]
Biological Activity: Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cabiralizumab | 99.73% | Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Weiss SA, et al. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clin Cancer Res. 2021 Sep 1;27(17):4757-4767. [Content Brief]
- [2]. Peyraud F, et al. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep. 2017 Sep 5;19(11):70. [Content Brief]
- [3]. Djureinovic D, et al. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Mol Cancer. 2023 Nov 14;22(1):182. [Content Brief]
- [4]. Arnoletti JP, et al. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation. PLoS One. 2022 Mar 22;17(3):e0265725. [Content Brief]
Keywords
